Général Actualités Oxurion NV to Present at 2019 Biotech Showcase Conference and Participate in CEO Power Breakfast Roundtable during the 37th Annual J.P. Morgan Healthcare Conference EN décembre 19, 2018
Général Actualités Oxurion and Beta Therapeutics To Develop New Heparanase Inhibitors for Treatment of dry AMD EN novembre 5, 2018
Général Actualités Oxurion NV Announces the Appointment of Adrienne Graves to its Board of Directors EN octobre 29, 2018
Général Actualités Oxurion NV to Present at the Upcoming Ophthalmology Innovation Summit and Provide a Clinical Update at the American Academy of Ophthalmology 2018 Annual Meeting EN octobre 24, 2018
Général Actualités Oxurion NV Extends Partnership with Retina Global in Support of Bolivian Diabetic Retinopathy (BOLDR) Project EN octobre 22, 2018
Général Actualités Oxurion nv Enrolls First Patient in Phase 1 Clinical Trial Evaluating THR-687, a Novel Pan-RGD Integrin Antagonist, for Treatment of Diabetic Macular Edema (DME) EN septembre 20, 2018
Général Actualités Oxurion Enrolls First Patient in Phase 2 Clinical Study Evaluating THR-317 (anti-PlGF) for treatment of Idiopathic Macular Telangiectasia Type 1 (MacTel 1) EN septembre 20, 2018
Général Actualités Oxurion NV to present further scientific findings supporting therapeutic potential of THR-317 and THR-687 as promising new therapies for Diabetic Eye Disease at upcoming EURETINA 2018 in Vienna, Austria EN septembre 17, 2018
Général Actualités Oxurion NV Announces New Euronext Brussels Stock Ticker “OXUR” and Launch of New Website EN septembre 10, 2018
Actualités Transparence/Dénominateur Regulated Information – Transparency Statement EN NL juillet 27, 2018
Général Actualités ThromboGenics Reports Day 150 Topline Data from its Phase 1/2 Clinical Study evaluating THR-317 (anti-PlGF) for the Treatment of Diabetic Macular Edema (DME) EN juillet 19, 2018
Général Actualités ThromboGenics Partners with Prevent Blindness at 2018 Focus on Eye Health National Summit in Washington DC EN juin 21, 2018
Général Actualités ThromboGenics Enrolls First Patient in Phase 1 Clinical Study Evaluating THR-149, a plasma kallikrein inhibitor, for treatment of Diabetic Macular Edema (DME) EN mai 25, 2018
Général Actualités ThromboGenics to present a preclinical overview of its two most advanced diabetic eye disease clinical candidates, THR-317 and THR-149, at EASDec 2018 EN mai 23, 2018
Général Actualités ThromboGenics Presenting Industry Expertise and Developments at Bio€quity Europe and Knowledge for Growth meetings in Ghent, Belgium EN mai 14, 2018
